What is the treatment with Mobocetinib
Mobocetinib is an oral EGFR tyrosine kinase inhibitor specifically targeting EGFR exon 20 insertion mutations, used to treat non-small cell lung cancer (NSCLC) patients.
1. Main treatment for diseases
(1) Non small cell lung cancer: suitable for treating locally advanced or metastatic adult patients with EGFR exon 20 insertion mutations.
2 Applicable Population
(1) EGFR exon 20 insertion mutation patients: NSCLC patients confirmed by FDA approved testing methods to have EGFR exon 20 insertion mutations.
(2) Patients with previous treatment failures: suitable for patients with disease progression during or after previous platinum based chemotherapy.
3 Characteristics of Function
(1) Targeted therapy: Specific inhibition of EGFR exon 20 insertion mutation fills the gap in targeted therapy for this mutation type.
(2) Oral administration: convenient for patients to use and improves treatment compliance.
(3) Breakthrough therapy: Targeting patients with EGFR exon 20 insertion mutations who have poor efficacy with traditional EGFR-TKI.
- Previous:Valcyte treatment scope
- Next:What disease does Ruxolitinib treat
Disclaimer：《What is the treatment with Mobocetinib》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！